Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 6721 - 6728 of 12092 results
What Does the EEOC’s Lawsuit Against Estee Lauder Mean for Parental Leave Policies?
September 27, 2017| Blog| Viewpoint
Making the Sausage: Lower Courts Grapple With the Supreme Court’s TC Heartland Venue Decision
September 27, 2017| Blog| Viewpoint
“In Light of the Specification”: Federal Circuit Weighs in on the Broadest Reasonable Interpretation
September 27, 2017| Blog| Viewpoint
New Qui Tam Update from Mintz’s Health Care Enforcement Defense Group
September 27, 2017| Blog| Viewpoint
Building a Health App? Part Two: Protecting Your Intellectual Property
September 26, 2017| Blog| Viewpoint
Latest Travel Restrictions from Trump Administration
September 26, 2017| Alert| Viewpoint
Book Review: Privacy in the Workplace
September 26, 2017| News
Fractal Geometry, Actuarial Risk, and §1332 Waivers—The Role of the States in Reforming Health Care
September 25, 2017| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|